Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

A. Hauschild, R. Dummer, D. Schadendorf, M. Santinami, V. Atkinson, M. Mandalà, V. Chiarion-Sileni, J. Larkin, M. Nyakas, C. Dutriaux, A. Haydon, C. Robert, L. Mortier, J. Schachter, T. Lesimple, R. Plummer, K. Dasgupta, T. Haas, M. Shilkrut, E. GasalR. Kefford, J.M. Kirkwood, G.V. Long

Research output: Contribution to journalArticlepeer-review

Original languageUndefined/Unknown
Pages (from-to)3441-3449
Number of pages9
JournalJournal of Clinical Oncology
Issue number35
Publication statusPublished - 2018

Cite this